Avaliação da função pulmonar de pacientes oncológicos submetidos a quimioterapia
Lizandra Dias Magno, Bianca Silva da Cruz, Karina Carvalho Marques, William Rafael Almeida Moraes, Leonardo Breno do Nascimento de Aviz, Beatriz da Costa Ferreira, Saul Rassy Carneiro, Laura Maria Tomazi Neves
Resumo
Introdução: O tratamento quimioterápico pode apresentar alguns efeitos adversos já conhecidos. No sistema respiratório, há evidências de alterações patológicas e funcionais decorrentes do tratamento do câncer, contudo, as implicações da quimioterapia sobre o sistema respiratório ainda não são amplamente documentadas. Objetivo: Analisar a função pulmonar de pacientes oncológicos submetidos ao tratamento de quimioterapia. Métodos: Estudo longitudinal, prospectivo com 14 pacientes em tratamento quimioterápico para câncer, com idade ≥18 anos e mínimo de 1 ciclo de quimioterapia. Por meio da espirometria foram analisadas Capacidade Vital Forçada (CVF), Volume Expiratório Forçado no Primeiro Segundo (VEF1), Índice de Tiffeneau (VF1/CVF), Fluxo Expiratório Forçado entre 25% e 75% da curva de CVF (FEF27-75%) e Pico de Fluxo Expiratório Forçado (PEF). 30 dias após o primeiro contato, os participantes foram reavaliados seguindo o mesmo protocolo. As análises dos dados foram realizadas no programa estatístico BioEstat versão 5.3, aplicando teste de Wilcoxon para comparação entre valores obtidos e valores preditos, considerando significância de p≤0,05. Resultados: Não houve diferença estatística entre as duas coletas, no entanto, com exceção do Índice de Tiffeneau, todas as outras medidas diferem estatisticamente do parâmetro de normalidade. Já na CVF e VEF1 os índices estiveram abaixo do limite padronizado. Além disso, o FEF25-75% apresentou escores maiores que esse parâmetro nas duas coletas, bem como o Índice de Tiffeneau Conclusão: A função pulmonar dessa população apresentou limitações, embora não se possa atribuir diretamente tal fato à ação dos quimioterápicos
Palavras-chave
Referências
1. Stein Y, Rotter V, Aloni-Grinstein R. Gain-of-function mutant p53: all the roads lead to tumorigenesis. Int J Mol Sci. 2019;20(24):6197. http://dx.doi.org/10.3390/ijms20246197. PMid:31817996.
2. Wang Z, Sha HH, Li HJ. Functions and mechanisms of miR-186 in human cancer. Biomed Pharmacother. 2019;119:109428. http://dx.doi.org/10.1016/j.biopha.2019.109428. PMid:31525641.
3. INCA: Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2019 [citado em 2021 Maio 19]. Disponível em: https://www.inca.gov.br/sites/ ufu.sti.inca.local/files/media/document/estimativa-2020- incidencia-de-cancer-no-brasil.pdf
4. Olgen S. Overview on anticancer drug design and development. Curr Med Chem. 2018 Maio 7;25(15):1704-19. http://dx.doi.org/10.2174/0929867325666171129215610. PMid:29189124.
5. Klein-Júnior LC, Campos A, Niero R, Corrêa R, Vander Heyden Y, Cechinel V Fo. Xanthones and cancer: from natural sources to mechanisms of action. Chem Biodivers. 2020;17(2):e1900499. http://dx.doi.org/10.1002/ cbdv.201900499. PMid:31794156.
6. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TML, Myklebust TÅ, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493-505. http://dx.doi.org/10.1016/ S1470-2045(19)30456-5. PMid:31521509.
7. Molina-Garrido MJ. Repercusión de los fármacos antineoplásicos sobre la situación nutricional del paciente oncogeriátrico. ¿Puede el oncólogo médico minimizar el impacto de estos fármacos sobre el estado nutricional del enfermo mayor? Nutr Hosp. 2020;34(1):22-30. http://dx.doi. org/10.20960/nh.02986. PMid:32559110.
8. Mosa ASM, Hossain AM, Lavoie BJ, Yoo I. . Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol. 2020;11:329. http:// dx.doi.org/10.3389/fphar.2020.00329. PMid:32296333.
9. Wang K, Zhang T, Lei Y, Li X, Jiang J, Lan J, et al. Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux. Autophagy. 2018;14(2):269-82. http://dx.doi.org/10.10 80/15548627.2017.1409405. PMid:29172997.
10. Eren MF, Ay Eren A, Sayan M, Yücel B, Elagöz Ş, Özgüven Y, et al. The impact of everolimus and radiation therapy on pulmonary fibrosis. Medicina. 2020;56(7):1-9. http://dx.doi. org/10.3390/medicina56070348. PMid:32668776.
11. Gomez D, Calderón C, Carmona-Bayonas A, Cacho Lavin D, Muñoz MM, Martinez Cabañez R, et al. Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis. Clin Transl Oncol. 2021 Mar;23(3):657-62. http://dx.doi.org/10.1007/ s12094-020-02454-z. PMid:32676895.
12. Albitar HAH, Duma N, Leventakos K, Moraes AG. Pulmonary complications secondary to immun checkpoint Inhibitors. Int J Chronic Dis. 2020;2020:4928648. http://dx.doi. org/10.1155/2020/4928648. PMid:32373643.
13. Perros F, Günther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, et al. Mitomycin-induced pulmonary venoocclusive disease: evidence from human disease and animal models. Circulation. 2015;132(9):834-47. http://dx.doi. org/10.1161/CIRCULATIONAHA.115.014207. PMid:26130118.
14. Kanaji N, Shimizu J, Sakai K, Ueda Y, Miyawaki H, Watanabe N, et al. Clinical features of patients with small cell lung cancer and idiopathic pulmonar fibrosis treated with chemotherapy or chemoradiotherapy. Ther Adv Respir Dis. 2020;14(1):1- 12. http://dx.doi.org/10.1177/1753466620963866. PMid:33086985.
15. Roden AC, Camus P. Iatrogenic pulmonary lesions. Semin Diagn Pathol. 2018;35(4):260-71. http://dx.doi.org/10.1053/j. semdp.2018.03.002. PMid:29631763.
16. Abdullah M, Alam S, Zafar W, Majid A. Diffusion lung capacity changes in hodgkin lymphoma patients before and after abvd chemotherapy. J Ayub Med Coll Abbottabad. 2016;28(2):289-92. PMid:28718544.
17. Jessurun NT, Drent M, Van Puijenbroek EP, Bekers O, Wijnen PA, Bast A. Drug-induced interstitial lung disease: role of pharmacogenetics in predicting cytotoxic mechanisms and risks of side effects. Curr Opin Pulm Med. 2019;25(5):468- 77. http://dx.doi.org/10.1097/MCP.0000000000000590. PMid:31365381.
18. Pereira CAC, Jansen JM, Barreto SSM, Marinho J, Sulmonett N, Dias RM. Espirometria. J Bras Pneumol. 2002;28(3):1-82. http://dx.doi.org/10.1001/jamaoncol.2019.2996.
19. Pereira CAC, Sato T, Rodrigues SC. Novos valores de referência para espirometria forçada em brasileiros adultos de raça branca. J Bras Pneumol. 2007 Ago;33(4):397-406. http://dx.doi. org/10.1590/S1806-37132007000400008. PMid:17982531.
20. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749-68. http://dx.doi. org/10.1001/jamaoncol.2019.2996. PMid:31560378.
21. Sciubba F, Spagnoli M, Iavicoli S, Asaro G, De Luca A, Guglielmi G, et al. Efficacy of sodium hypochlorite in the degradation antineoplastic drugs by NMR spectroscopy. G Ital Med Lav Ergon. 2020 Jun;42(2):109-20. PMid:32614541.
22. Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study. PLoS One. 2017;12(10):e0184360. http:// dx.doi.org/10.1371/journal.pone.0184360. PMid:29016607.
23. Lin L, Yan L, Liu Y, Yuan F, Li H, Ni J. Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol. 2019;12(1):96. http://dx.doi.org/10.1186/s13045-019- 0783-9. PMid:31511035.
24. Miranda AC, Caldato C, Said MN, Levy CS, Teixeira CEC, Quaresma JAS. Gender, age, endoscopic findings, urease and helicobacter pylori: all uncorrelated within a sample of a high gastric cancer prevalence population in Amazon. Arq Gastroenterol. 2019;56(3):264-9. http://dx.doi.org/10.1590/ s0004-2803.201900000-50. PMid:31633723.
25. Lin B, Kennedy B, McBride J, Dalla-Pozza L, Trahair T, McCowage G, et al. Long-term morbidity of respiratory viral infections during chemotherapy in children with leukaemia. Pediatr Pulmonol. 2019;54(11):1821-9. http:// dx.doi.org/10.1002/ppul.24456. PMid:31393087.
26. Müller AM, Silva DR, Xavier RG. Avaliação da qualidade de vida e função pulmonar em pacientes com câncer de pulmão. Clin Biomed Res. 2014;34(4):347-56. http://dx.doi. org/10.4322/2357-9730.48568.
27. Elliott JA, O’Byrne L, Foley G, Murphy CF, Doyle SL, King S, et al. Effect of neoadjuvant chemoradiation on preoperative pulmonary physiology, postoperative respiratory complications and quality of life in patients with oesophageal cancer. Br J Surg. 2019;106(10):1341-51. http:// dx.doi.org/10.1002/bjs.11218. PMid:31282584.
28. Dietz AC, Chen Y, Yasui Y, Ness KK, Hagood JS, Chow EJ, et al. Risk and impact of pulmonary complications in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2016;122(23):3687-96. http://dx.doi. org/10.1002/cncr.30200. PMid:27504874.
29. Torre-Bouscoulet L, Arroyo-Hernández M, Martínez-Briseño D, Muñoz-Montaño WR, Gochicoa-Rangel L, Bacon-Fonseca L, et al. Longitudinal evaluation of lung function in patients with advanced non-small cell lung cancer treated with concurrent chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2018;101(4):910-8. http://dx.doi.org/10.1016/j. ijrobp.2018.04.014. PMid:29976503.
30. Abreu APM, Endres D, Bortoluzzi Costa A, Cecagno Zanini SC, Ribeiro Martini R, Pereira Leguisamo C. Função pulmonar e força muscular respiratória em pacientes submetidas à cirurgia oncológica de mama. Rev Bras Cancerol. 2014;60(2):151-7. http://dx.doi.org/10.32635/2176-9745.RBC.2014v60n2.484.
31. Burtin C, Franssen FME, Vanfleteren LEGW, Groenen MTJ, Wouters EFM, Spruit MA. Lower-limb muscle function is a determinant of exercise tolerance after lung resection surgery in patients with lung cancer. Respirology. 2017;22(6):1185-9. http://dx.doi.org/10.1111/resp.13041. PMid:28370836.
32. Brocki BC, Andreasen JJ, Langer D, Souza DSR, Westerdahl E. Postoperative inspiratory muscle training in addition to breathing exercises and early mobilization improves oxygenation in highrisk patients after lung cancer surgery: a randomized controlled trial. Eur J Cardiothorac Surg. 2016;49(5):1483-91. http://dx.doi. org/10.1093/ejcts/ezv359. PMid:26489835.
33. Higuchi M, Takagi H, Ozaki Y, Inoue T, Watanabe Y, Yamaura T, et al. Comparison of surgical outcomes after pneumonectomy and pulmonary function-preserving surgery for non-small cell lung cancer. Fukushima J Med Sci. 2018;64(1):30-7. http:// dx.doi.org/10.5387/fms.2017-10. PMid:29459574.
34. Dana Oprea A. Chemotherapy agents with known pulmonary side effects and their anesthetic and critical care implications. J Cardiothorac Vasc Anesth. 2017;31(6):2227-35. http:// dx.doi.org/10.1053/j.jvca.2015.06.019. PMid:26619953.
35. Caponero R, Montarroyos ES, Tahamtani SMM. Postchemotherapy neuropathy. Rev Dor. 2016;17(Supl. 1):56-8. http://dx.doi.org/10.5935/1806-0013.20160049.
36. Satoh T, Gemma A, Kudoh S, Sakai F, Yamaguchi K, Watanabe T, et al. Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry. Jpn J Clin Oncol. 2014;44(11):1032-9. http://dx.doi.org/10.1093/ jjco/hyu128. PMid:25210144.
37. Necchi A, Miceli R, Oualla K, Sonpavde G, Giannatempo P, Raggi D, et al. Effect of bleomycin administration on the development of pulmonary toxicity in patients with metastatic germ cell tumors receiving first-line chemotherapy: a meta-analysis of randomized studies. Clin Genitourin Cancer. 2017;15(2):213-220.e5. http://dx.doi. org/10.1016/j.clgc.2016.08.021. PMid:27692810.
38. Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V, et al. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 2019;26:25. http://dx.doi.org/10.1186/s12929-019-0518-9. PMid:30866950.
39. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10. http://dx.doi. org/10.1177/1758835918780140. PMid:29977352.
Submetido em:
19/05/2021
Aceito em:
21/09/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email